WAWalter Alarco

Walter Alarco

*This is an algorithmically generated author record based on publicly available information.

Walter Alarco has a total of 76 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Pulmonary embolism or a fatal mimic? Wall-eclipsing sign and metastatic tissue diagnosis in pulmonary artery intimal sarcoma: a case report

    by Alexis Vallejos Barrientos, Kevin Lévano Carpio, Rolando Chapilliquen Chuyes, Iván García Gómez, Germán Salazar Aldea, Walter Alarco León

    Background: Pulmonary artery intimal sarcoma is a rare, aggressive malignancy that may mimic chronic pulmonary infection and chronic thromboembolic disease. This case highlights the need to reconsider a thromboembolic diagnosis when pulmonary arterial obstruction persists despite anticoagulation and is associated with the wall-eclipsing sign and progressive right ventricular failure. Case summary: A 50-year-old woman presented with 3 months of intermittent haemoptysis and progressive dyspnoea. Initial evaluation suggested chronic infectious lung disease; however, transthoracic echocardiography identified a mass involving the main pulmonary artery. Computed tomography pulmonary angiography was initially interpreted as chronic pulmonary thromboembolism, and anticoagulation was initiated. Shortly thereafter, life-threatening haemoptysis required high-flow nasal oxygen therapy, transfusion of four units of packed red blood cells, and vasopressor support. Follow-up imaging showed persistent pulmonary arterial obstruction with progressive right ventricular failure. Repeat computed tomography pulmonary angiography demonstrated an infiltrative pulmonary artery mass with intrinsic enhancement, left atrial extension, and the wall-eclipsing sign. Breast nodules and axillary lymphadenopathy prompted biopsy of an accessible breast lesion, which revealed a high-grade spindle-cell neoplasm with CD31 and ERG expression, supporting angiosarcomatous differentiation, together with nuclear MDM2 immunoreactivity. Fluorescence in situ hybridization demonstrated MDM2 gene amplification in the breast biopsy, supporting the integrated diagnosis of pulmonary artery intimal sarcoma with angiosarcomatous differentiation and breast metastasis. Discussion: This case highlights the need to reconsider chronic thromboembolic disease when pulmonary arterial obstruction persists despite anticoagulation, particularly in the presence of the wall-eclipsing sign. Metastatic tissue sampling may establish the diagnosis while avoiding high-risk intravascular biopsy.

  • Open Access

    Comorbidity Clusters in Acute Heart Failure: Insights From the AMERICCAASS Registry

    by Juan Pablo Arango‐Ibanez, Sebastián Seni‐Molina, Juan Andrés Muñoz‐Ordoñez, Valeria Azcárate‐Rodríguez, Andrea Valencia‐Orozco, Mario Miguel Barbosa Rengifo, Luis Eduardo Echeverría Correa, Adrián Lescano, Juan Pablo Allende, Tessa Negrín Valdés, et al.

    Background: Acute heart failure (HF) frequently coexists with multimorbidity. Comorbidity clusters have been associated with distinct clinical outcomes, but data from the Americas remain limited. We aimed to identify comorbidity clusters in patients with acute HF and assess their association with in‐hospital outcomes. Methods: This cohort study applied latent class analysis to patients from the AMERICCAASS Registry (Registro Americano de Insuficiencia Cardiaca Ambulatoria o Agudamente descompensada). Adjusted Poisson regression assessed in‐hospital mortality and intensive care unit (ICU) admission, and multivariable analysis identified independent predictors of ICU admission. Results: Among 1638 patients, 60.6% were men and the median age was 67.2 years. Hypertension (69.4%), smoking (40.3%), and coronary artery disease (33.8%) were common comorbidities. Cluster 1 (Young, n=828) included the youngest patients (median age 63.2 years) with the fewest comorbidities. Cluster 2 (Cardio‐Kidney‐Metabolic, n=512) represented the oldest group (median age 71.8 years) with the highest median body mass index (27.7 kg/m 2 ), the greatest proportion of HF with mildly reduced or preserved ejection fraction (44.7%), and a high comorbidity burden. Cluster 3 (“Ischemic,” n=298) was characterized by older patients (median age 70.2 years) with an exceptionally high prevalence of coronary artery disease (96.3%) and the greatest proportion of HF with reduced ejection fraction (61.4%). ICU admission risk was higher in Cluster 2 (adjusted risk ratio [aRR], 1.15 [95% CI, 1.03–1.27]; P =0.009) and Cluster 3 (aRR, 1.25 [95% CI, 1.12–1.39]; P <0.001), compared with Cluster 1. Severe valvular insufficiency, peripheral artery disease, dyslipidemia, cancer, acute coronary syndrome, anemia, and cardiogenic shock were associated with higher ICU admission risk. Conclusions: Patients with acute HF in the Americas exhibit distinct comorbidity patterns associated with different clinical profiles and ICU admission rates, which may inform risk stratification and management strategies. Registration: URL: https://www.clinicaltrials.gov ; Unique Identifier: NCT05295641.


  • Open Access

    Association of Abnormal Cardiac Biomarkers and Cardiovascular Complications, with Mortality in Patients with SARS-CoV-2 Infection in Latin America

    by Juan Esteban Gómez-Mesa, Manuela Escalante, Juan Andrés Muñoz-Ordoñez, Valeria Azcárate-Rodriguez, Juan David Peláez-Martínez, Andrea Alejandra Arteaga-Tobar, Hoover León-Giraldo, Andrea Valencia-Orozco, Eduardo Roque Perna, Alexander Romero, et al.

    Background: The COVID-19 pandemic has highlighted a correlation between cardiac complications and elevated cardiac biomarkers, which are linked to poorer clinical outcomes. Objective: This study aims to determine the clinical impact of cardiac biomarkers in COVID-19 patients in Latin America. Subjects and methods: The CARDIO COVID 19-20 Registry is a multicenter observational study across 44 hospitals in Latin America and the Caribbean. It included hospitalized COVID-19 patients (n = 476) who underwent troponin, natriuretic peptide, and D-dimer tests. Patients were grouped based on the number of positive biomarkers. Results: Among the 476 patients tested, 139 had one positive biomarker (Group C), 190 had two (Group B), 118 had three (Group A), and 29 had none (Group D). A directly proportional relationship was observed between the number of positive biomarkers and the incidence of decompensated heart failure. Similarly, there was a proportional relationship between the number of positive biomarkers and increased mortality. In Group B, patients with elevated troponin and natriuretic peptide and those with elevated troponin and D-dimer had 1.4 and 1.5 times higher mortality, respectively, than those with elevated natriuretic peptide and D-dimer. Conclusions: In Latin American COVID-19 patients, a higher number of positive cardiac biomarkers is associated with increased cardiovascular complications and mortality. These findings suggest that cardiac biomarkers should be utilized to guide acute-phase treatment strategies.


  • Open Access

    Cardiovascular Complications in Patients with Heart Failure and COVID-19: CARDIO COVID 19-20 Registry

    by Mario Speranza, Juan D. López-López, Pedro Schwartzmann, Igor Morr, María Juliana Rodríguez-González, Andrés Buitrago, Freddy Pow-Chon-Long, Luiz Carlos Passos, Víctor Rossel, Eduardo Roque Perna, et al.

    Since early 2020, different studies have shown an increased prevalence of COVID-19 and poorer prognosis in older adults with cardiovascular comorbidities. This study aimed to assess the impact of heart failure (HF) on cardiovascular complications, intensive care unit (ICU) admissions, and in-hospital mortality in patients hospitalized with COVID-19. The CARDIO COVID 19-20 registry includes 3260 hospitalized patients with a COVID-19 serological diagnosis between May 2020 and June 2021 from Latin American countries. A history of HF was identified in 182 patients (5.6%). In patients with and without previous HF, the incidence of supraventricular arrhythmia was 16.5% vs. 6.3%, respectively (p = 0.001), and that of acute coronary syndrome was 7.1% vs. 2.7%, respectively (p = 0.001). Patients with a history of HF had higher rates of ICU admission (61.5% vs. 53.1%, respectively; p = 0.031) and in-hospital mortality (41.8% vs. 24.5%, respectively; p = 0.001) than patients without HF. Cardiovascular mortality at discharge (42.1% vs. 18.5%, respectively; p < 0.001) and at 30 days post-discharge (66.7% vs. 18.0%, respectively) was higher for patients with a history of HF than for patients without HF. In patients hospitalized with COVID-19, previous history of HF was associated with a more severe cardiovascular profile, with increased risk of cardiovascular complications, and poor in-hospital and 30-day outcomes.


  • Open Access

    Latin-American Registry of Cardiovascular Disease and COVID-19: Final Results

    by Juan Esteban Gomez-Mesa, Stephania Galindo, Manuela Escalante-Forero, Yorlany Rodas, Andrea Valencia, Eduardo Perna, Alexander Romero, Iván Mendoza, Fernando Wyss, José Luis Barisani, et al.

    Background: Socioeconomic factors contribute to a more severe impact of COVID-19 in Latin American and Caribbean (LA&C) countries than in developed countries. Patients with a severe or critical illness can develop respiratory and cardiovascular complications. Objective: To describe a LA&C population with COVID-19 to provide information related to this disease, in-hospital cardiovascular complications, and in-hospital mortality. Methods: The CARDIO COVID-19–20 Registry is an observational, multicenter, prospective, and hospital-based registry of patients with confirmed COVID-19 infection that required in-hospital treatment in LA&C. Enrollment of patients started on May 01, 2020, and ended on June 30, 2021. Results: The CARDIO COVID-19–20 Registry included 3260 patients from 44 institutions of 14 LA&C countries. 63.2% patients were male and median age was 61.0 years old. Most common comorbidities were overweight/obesity (49.7%), hypertension (49.0%), and diabetes mellitus (26.7%). Most frequent cardiovascular complications during hospitalization or reported at discharge were cardiac arrhythmia (9.1%), decompensated heart failure (8.5%), and pulmonary embolism (3.9%). The number of patients admitted to the Intensive Care Unit (ICU) was 1745 (53.5%), and median length of their stay at the ICU was 10.0 days. Support required in ICU included invasive mechanical ventilation (34.2%), vasopressors (27.6%), inotropics (10.3%), and vasodilators (3.7%). Rehospitalization after 30-day post discharge was 7.3%. In-hospital mortality and 30-day post discharge were 25.5% and 2.6%, respectively. Conclusions: According to our findings, more than half of the LA&C population with COVID-19 assessed required management in ICU, with higher requirement of invasive mechanical ventilation and vasoactive support, resulting in a high in-hospital mortality and a considerable high 30-day post discharge rehospitalization and mortality.


  • Open Access

    Características epidemiológicas de receptores de trasplante cardiaco en el Perú, 2010-2020

    by Gracia del Carmen Polo Lecca, Franz Ronald Soplopuco Palacios, Walter Alberto Alarco León, Oscar Nelson Aguirre Zurita, Cristian Aguilar Carranza, Ruth Eneida Villarroel Villa, Tommy Leonel Prado Gómez, José Luis Tapia Leonardo, Miguel Ángel Lescano Alva, Víctor Justo Robles Velarde, et al.

    Objetivo. Evaluar las características epidemiológicas, clínicas, quirúrgicas, patológicas y desenlaces en el seguimiento de los pacientes receptores de trasplante cardiaco en el Instituto Nacional Cardiovascular durante 2010-2020. Materiales y métodos. Estudio retrospectivo descriptivo de pacientes sometidos a trasplante cardiaco en un centro de referencia nacional, se describen las características clínicas, quirúrgicas, de laboratorio, de patología y la supervivencia de los pacientes hasta los 10 años de seguimiento. Resultados. Ochenta y seis pacientes fueron trasplantados en 10 años, la mediana de edad fue de 41 años (RIQ 28-56), con predominancia de varones (66,3%). Las tres primeras causas de indicación de trasplante cardiaco fueron: cardiomiopatía dilatada (48,9%), cardiopatía isquémica (17,4%) y miocarditis (6,9%). El tiempo de isquemia total fue de 160 min (RIQ 129,7-233,5). La sobrevida al año, cinco y diez años fue de 84,8%, 73,6% y 65,7%, respectivamente. La principal causa de muerte fue la infecciosa (39,1%) y de origen desconocido (26%). Conclusiones. La principal etiología de la insuficiencia cardiaca en el receptor de trasplante cardiaco en el Perú, en los últimos años, fue la cardiomiopatía dilatada no isquémica. Se observa que la tasa de sobrevida fue similar a la de registros internacionales; sin embargo, la tasa de mortalidad de causa infecciosa y muerte de origen desconocido es alta, lo cual plantea un desafío en el manejo de los pacientes postrasplante.

  • Open Access

    Taquicardia atrial focal incesante como causa de cardiomiopatía. A propósito de un caso

    by Juan Manuel Muñoz Moreno, Carlos Lobato Jeri, Richard Soto Becerra, Luis Parada Porras, Walter Alarco León

    Focal atrial tachycardia is a rare type of supraventricular tachyarrhythmia, generally present in young people, and is a rare cause of tachycardiomyopathy (10%). We present a clinical case of tachycardiomyopathy in a 30-year-old man, without comorbidities, who was diagnosed with incessant focal atrial tachycardia, refractory to medical therapy, and electrical cardioversion. Succesful endocardial ablation was performed, and in outpatient follow-up at 6 months, he showed a recovery of the left ventricular ejection fraction and reduction of the left chambers to normal ranges, with progressive decrease of dyspnea.

  • Open Access

    Diabetes e Insuficiencia Cardíaca

    by Walter Alarco

    Diabetes Mellitus (DM) is a chronic non-communicable cardio-metabolic disease that causes macro-vascular complications such as atherosclerosis, coronary disease and heart failure (HF). There is a bidi- rectional relationship between HF and DM, HF being the second most frequent initial cardiovascular event in patients with diabetes. It may even be the first cardiovascular complication, before acute my- ocardial infarction.DM can lead to HF through mechanisms mediated by atherosclerosis and non mediated by it. In the first case, cholesterol is deposited in coronary arteries, favored by the presence of other risk factors. In the second case, the myocardium is directly affected leading to structural and functional changes through non-atherogenic mechanisms (called Diabetic Cardiomyopathy).The treatment of HF with reduced ejection fraction in the diabetic patient does not differ from that of the non-diabetic population, the triple neurohumoral block must be achieved. In the case of patients with HF with ejection fraction preserved to date, we do not have specific therapy to reduce cardiovas- cular morbidity and mortality. In the diabetes treatment of the patient with HF, sodium-glucose type 2 cotransporter inhibitors (SGLT2i) clearly stand out. In addition to their glucosuric and natriuretic effect, they have pleiotropic effects that produce metabolic, hemodynamic and cellular viability effects preventing apoptosis and cell death. Finally, the clinical benefits of SGLT2 inhibitors in HF go beyond glycemic control, as demon- strated by the DAPA-HF study; initiating a new era in the treatment of patients with HF with reduced ejection fraction.